Toward the back of every prescribing information document sits a section called Use in Specific Populations, and inside it, for most products, two short subsections: one on renal impairment, one on hepatic impairment. They are among the least read pages in the document, and they answer a question people assume is more complicated than it is. The class answer is broadly the same from product to product, and the exceptions are where the reading gets interesting.
One boundary before the substance. The acute kidney injury and volume depletion warning, and the dehydration that drives it, is a different subject carried in full at GLP-1s and Your Kidneys: Why Dehydration Is the Risk. This page is about the dosing subsections: what each label says, what was measured behind it, and what was not.
The class answer: no dosage adjustment
Most of the class gives a flat answer, and it is genuinely reassuring and genuinely boring. For Ozempic, no dose adjustment is recommended for patients with renal impairment; in subjects with renal impairment including kidney failure, no clinically relevant change in semaglutide pharmacokinetics was observed, and the hepatic entry says the same. The shared label for Rybelsus and Ozempic tablets states that the recommended dosage in patients with renal impairment is the same as in those with normal renal function, and likewise for hepatic impairment; its safety and effectiveness were evaluated in a 26-week study that included 324 patients with moderate renal impairment, eGFR 30 to 59.
Zepbound and Mounjaro reach furthest down the scale of kidney function. No dosage adjustment for renal impairment, with no change in tirzepatide pharmacokinetics observed in subjects with renal impairment including end-stage renal disease, and the same no-adjustment statement for hepatic impairment across mild, moderate and severe. Both labels also say to monitor renal function in people reporting adverse reactions that could lead to volume depletion. Victoza's renal entry carries a dedicated 26-week trial that included patients with moderate renal impairment alongside its no-adjustment statement.
Saxenda's silence, and Victoza's caution
Saxenda is the shortest entry in the class and makes no dosing statement at all for renal impairment. What its label says is that there is limited experience with Saxenda in patients with mild, moderate and severe renal impairment, including end-stage renal disease. The hepatic entry adds a caution on top of the same limited experience: use with caution in that population.
Victoza's hepatic entry does two things at once, and the pairing is worth pausing on. It states that there is limited experience in mild, moderate or severe hepatic impairment and therefore to use with caution, and, in the same entry, that no dose adjustment is recommended. Those are different instructions. Use with caution describes a posture for the prescriber; adjust the dose changes the regimen. A label can give one without the other, and this one gives the caution without the change.
GLP 1 Tracker AppDoses on their real schedules and side effects with dates and severity, so a prescriber reading your history sees the record rather than the recollection. Free, no account, nothing leaves your phone.
Get the app
Trulicity's measured numbers
Trulicity reports measurements rather than a flat sentence. Dulaglutide exposure was increased by 20, 28, 14 and 12 percent in mild, moderate, severe and end-stage renal disease groups compared with normal renal function, and decreased by 23, 33 and 21 percent in mild, moderate and severe hepatic impairment. The clinical conclusion is still that no overall differences in safety or effectiveness were observed by renal function, backed by a dedicated trial in moderate to severe chronic kidney disease, while for hepatic impairment the label says there is limited clinical experience and therefore to use Trulicity with caution.
The percentages are worth reading for what they are: measured differences in exposure between groups of people, reported as pharmacology rather than translated into a dosing instruction. They are also the clearest illustration in the class that no dosage adjustment is a conclusion a label reaches, not a statement that nothing was measured.
Wegovy, the outlier
The Wegovy label is the real exception, and it is structural. Its Use in Specific Populations section has no renal impairment subsection and no hepatic impairment subsection at all; the section runs Pregnancy, Lactation, Females and Males of Reproductive Potential, Pediatric Use, Geriatric Use, and then Type 2 Diabetes Mellitus. What the label says on the subject sits in two other places.
In Clinical Pharmacology, the Wegovy label states that no clinically significant differences in semaglutide pharmacokinetics were observed based on age, sex, race, ethnicity, body weight, upper GI disease, renal impairment with eGFR of 30 or above and below 90, or mild, moderate and severe hepatic impairment, Child-Pugh A to C. Note the bound: that statement covers eGFR down to 30 and no lower, where the Ozempic label says kidney failure and the tirzepatide labels say end-stage renal disease. In Adverse Reactions, the label states that the risk of renal adverse reactions with Wegovy was increased in adult patients with a history of renal impairment, from trials that included 65 patients with a history of moderate or severe renal impairment at baseline, and that those reactions occurred more frequently during dose titration.
The point deserves care. The same molecule has a diabetes label that addresses kidney failure explicitly and a weight-management label that does not carry the subsection at all and bounds its pharmacokinetics statement at eGFR 30. That is a difference in what each label documents, driven by what each program measured and where; it ranks nothing and settles nothing about either product.
What no dosage adjustment actually means
The transferable point fits in two sentences. No dosage adjustment is not the same as studied in depth: Wegovy's bound at eGFR 30, set against Ozempic's kidney failure language, shows two labels with the same practical headline describing different amounts of measurement. Limited experience is not the same as unsafe: it records what was and was not measured, not a signal of harm.
A label records what was measured and what the sponsor concluded. A reader's own kidneys or liver are not in it: the eGFR on a lab report and the Child-Pugh class on a workup are prescriber territory, and the impairment subsections are the floor rather than the answer. Reading a label's subsections against each other is the working method behind How to Read Your GLP-1's Prescribing Information, and what the labels do and do not ask for in monitoring is laid out at Blood Work on a GLP-1: Numbers Worth Keeping.
Frequently asked questions
Do I need a different GLP-1 dose if I have kidney disease?
For Ozempic, the Rybelsus and Ozempic tablets label, Zepbound, Mounjaro and Victoza, the labels state that no dosage adjustment is recommended for renal impairment, several of them backed by dedicated trials in moderate impairment. Trulicity does not use that phrasing: it reports that no overall differences in safety or effectiveness were observed according to renal function. Saxenda makes no dosing statement and reports limited experience. These are statements the labels make about studied populations, not permission for any individual dose, which is decided by a prescriber with the person's labs in front of them.
What does the Wegovy label say about kidney impairment?
Wegovy has no renal impairment subsection in its Use in Specific Populations section at all. Its pharmacokinetics statement covers renal impairment with eGFR of 30 or above and below 90, a lower bound short of Ozempic's kidney failure language and the tirzepatide labels' end-stage renal disease language, and its adverse reactions section reports an increased risk of renal adverse reactions in adults with a history of renal impairment, occurring more frequently during dose titration.
Can you take a GLP-1 if you have liver disease?
The hepatic entries vary in posture more than the renal ones do. Ozempic and the tirzepatide labels state no dosage adjustment, with no clinically relevant pharmacokinetic change across mild, moderate and severe impairment. Victoza pairs use with caution with no dose adjustment, while Saxenda and Trulicity carry a caution on the basis of limited experience. Which product suits a given person is a prescriber decision.
What does use with caution mean in a prescribing label?
It is a posture for the prescriber rather than an instruction to change the regimen. When a label says there is limited experience in a population and therefore to use with caution, it records that few people in that situation were studied, not that harm was observed. It differs from a dosing statement, and the two can appear together, as in Victoza's hepatic entry, which gives both the caution and no dose adjustment.
Does no dosage adjustment mean the drug was studied thoroughly in that population?
Not necessarily, and the class itself shows why. Trulicity reports measured exposure differences by renal and hepatic function and still concludes no adjustment is needed. Wegovy bounds its pharmacokinetics statement at eGFR 30 where other labels describe kidney failure or end-stage renal disease. Saxenda offers only limited experience with no dosing statement at all. The subsections record what was measured, and reading them for any individual belongs to a prescriber.